Zepbound vs Rybelsus: Price & Results Breakdown (2026)
Trying to choose between Zepbound (Tirzepatide) and Rybelsus (Semaglutide (oral))? Below we put the trial weight loss numbers, monthly cost, dosing, and tolerability head to head — and spell out the type of patient each one tends to fit best.
Zepbound (Tirzepatide, Dual GLP-1/GIP receptor agonist) and Rybelsus (Semaglutide (oral), GLP-1 receptor agonist) work through different mechanisms. Zepbound is FDA-approved for chronic weight management with 20-22% of body weight average weight loss at $1,060/mo. Rybelsus is approved for type 2 diabetes with 5-10% of body weight average weight loss at $936/mo.
The Numbers at a Glance
| Feature | Zepbound | Rybelsus |
|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide (oral) |
| Mechanism | Dual GLP-1/GIP receptor agonist | GLP-1 receptor agonist |
| FDA Approved For | Chronic weight management | Type 2 diabetes |
| Doses | 2.5mg to 15mg (weekly injection) | 3mg, 7mg, 14mg (daily oral tablet) |
| Administration | Weekly subcutaneous injection | Daily oral tablet on empty stomach |
| Avg. Weight Loss | 20-22% of body weight | 5-10% of body weight |
| Monthly Price | $1,060 | $936 |
| Oral Available | No | Yes |
| Year Approved | 2023 | 2019 |
- Zepbound
- Tirzepatide
- Rybelsus
- Semaglutide (oral)
- Zepbound
- Dual GLP-1/GIP receptor agonist
- Rybelsus
- GLP-1 receptor agonist
- Zepbound
- Chronic weight management
- Rybelsus
- Type 2 diabetes
- Zepbound
- 2.5mg to 15mg (weekly injection)
- Rybelsus
- 3mg, 7mg, 14mg (daily oral tablet)
- Zepbound
- Weekly subcutaneous injection
- Rybelsus
- Daily oral tablet on empty stomach
- Zepbound
- 20-22% of body weight
- Rybelsus
- 5-10% of body weight
- Zepbound
- $1,060
- Rybelsus
- $936
- Zepbound
- No
- Rybelsus
- Yes
- Zepbound
- 2023
- Rybelsus
- 2019
Figures shown are typical cash-pay prices before insurance. What you pay can differ by pharmacy, region, and your specific plan. Last updated March 2026.
Which Drops More Weight?
Based on clinical data, Zepbound produces more weight loss on average (20-22% of body weight) compared to Rybelsus (5-10% of body weight). Zepbound relies on Tirzepatide (Dual GLP-1/GIP receptor agonist), whereas Rybelsus uses Semaglutide (oral) (GLP-1 receptor agonist) — a likely reason for the gap.
Holds FDA approval for ongoing weight management and runs on the same compound as Mounjaro, tirzepatide. Among GLP-1 medications cleared today, it records the strongest average weight reduction.
The original GLP-1 medication taken by mouth. Because its dosing runs below injectable semaglutide, weight loss is more modest, but it suits anyone who would rather swallow a tablet than inject.
Which Is Easier on Your Wallet?
At list price, Rybelsus is the more affordable option at $936/month compared to $1,060/month for Zepbound. That said, what leaves your pocket swings hugely with your coverage. Zepbound with insurance: Varies by plan. Rybelsus with insurance: $10-$150/month typical copay.
Eligible patients can access the LillyDirect program
Savings programs from the manufacturer are offered
How the Side Effects Stack Up
Zepbound (Dual GLP-1/GIP receptor agonist) and Rybelsus (GLP-1 receptor agonist) bring on much the same digestive side effects, which top the list of what patients report:
- Nausea (most common for both medications)
- Diarrhea and vomiting
- Constipation
- Abdominal pain
- Decreased appetite
- Headache, fatigue, dizziness (less common)
Rarer but more serious risks for both drugs include pancreatitis, gallbladder complications, and kidney strain. Each also carries a boxed warning about medullary thyroid carcinoma seen in rodent studies. Go over your complete medical history with a clinician before you start either one.
So Which One Is Right for You?
There is no single winner — the right pick comes down to your diagnosis, what your plan covers, how much weight you want to lose, and how you feel about injections versus pills. Use the quick checklist below as a starting point:
- -Your primary goal is weight loss (FDA-approved indication)
- -You want the dual GLP-1/GIP mechanism for potentially greater efficacy
- -You prefer the convenience of once-weekly dosing
- -You have type 2 diabetes (on-label use, better insurance coverage)
- -You prefer an oral option over injections
- -Cost is a concern ($936/month at list price)
- -You prefer a daily dosing routine
See Who Prescribes These at the Lowest Price
Browse vetted telehealth programs that can prescribe Zepbound, Rybelsus, and other FDA-approved GLP-1 medications — ranked by what you will actually pay.
Common Questions, Answered
Can I switch from Zepbound to Rybelsus?
It can be done, but only under a prescriber's guidance, since Zepbound and Rybelsus rely on different active ingredients (Tirzepatide vs Semaglutide (oral)). Your clinician will set the right starting dose and titration plan for whichever medication you move to.
Which is better for weight loss: Zepbound or Rybelsus?
Clinical data suggests Zepbound produces more weight loss on average (20-22% of body weight) compared to Rybelsus (5-10% of body weight). However, individual results vary significantly based on dosing, diet, exercise, and metabolic factors.
Is Zepbound cheaper than Rybelsus?
At list price, Rybelsus ($936/month) is less expensive than Zepbound ($1,060/month). With insurance, costs vary significantly. Zepbound: Varies by plan. Rybelsus: $10-$150/month typical copay.
Do Zepbound and Rybelsus have the same side effects?
They overlap a lot. Stomach-related effects like nausea, diarrhea, vomiting, and constipation show up with both because they are typical of GLP-1 receptor agonists. That said, the different active ingredients mean how often and how strongly they hit can differ — talk through your history with a clinician to see which is the safer fit for you.
Does insurance cover Zepbound and Rybelsus?
Coverage varies by plan. Zepbound is FDA-approved for chronic weight management — insurance coverage is typically better for on-label use. Rybelsus is FDA-approved for type 2 diabetes. Check with your specific insurance plan and ask your doctor about prior authorization requirements.